Rationale and design of Short-Term EXenatide therapy in Acute ischaemic Stroke (STEXAS): a randomised, open-label, parallel-group study.

Introduction: Both hyperglycaemia and hypoglycaemia in acute ischaemic stroke (AIS) are associated with increased infarct size and worse functional outcomes. Thus, therapies that can maintain normoglycaemia during stroke are clinically important. Glucagon-like peptide 1 (GLP-1) analogues, including exenatide, are routinely used in the treatment of hyperglycaemia in type 2 diabetes, but data on the usefulness of this class of agents in the management of elevated glucose levels in AIS are limited.

Rapid access point of care clinic for transient ischemic attacks and minor strokes.

We present 24months of prospective data from a new model of care for transient ischemic attacks (TIA) and minor stroke, established at the Royal North Shore Hospital, a tertiary teaching hospital in Sydney, Australia. Prior to 2011, approximately 200 patients were admitted to our emergency department (ED) annually, following presentation with a suspected TIA. These patients had an average length of stay of 5.

Depression but not anxiety predicts recurrent cerebrovascular events.

Objectives: Depression and anxiety after stroke occur frequently and have been suggested to have negative influence on functional outcomes. However, the effect of emotional symptoms on stroke recurrence is uncertain. The aim of this study was to define the effect of emotional symptoms on recurrent cerebrovascular events in patients with ischemic stroke.

Endovascular therapy for ischemic stroke with perfusion-imaging selection.

Background: Trials of endovascular therapy for ischemic stroke have produced variable results. We conducted this study to test whether more advanced imaging selection, recently developed devices, and earlier intervention improve outcomes.

Methods: We randomly assigned patients with ischemic stroke who were receiving 0.